

Table 1. Proportion of pediatric patients who achieved seizure freedom from POS, SGS, or PGTCS during the Core Study Maintenance Period and then remained seizure free for 6 and/or 12 months during Extension A Phase by EIASM use and age group

	POS	SGS	PGTCS
EIASM use (with/without), n (%)			
6 months			
with	3/5 (60.0)	0/1 (0)	0 ^a
without	10/12 (83.3)	3/7 (42.9)	6/10 (60.0)
12 months			
with	2/5 (40.0)	0/1 (0)	0 ^a
without	4/6 (66.7)	1/4 (25.0)	3/7 (42.9)
Age (4–<7 years, 7–<12 years), n (%)			
6 months			
4–<7 years	1/3 (33.3)	0/3 (0)	1/2 (50.0)
7–<12 years	12/14 (85.7)	3/5 (60.0)	5/8 (62.5)
12 months			
4–<7 years	0/1 (0)	0/2 (0)	0/1 (0)
7–<12 years	6/10 (60.0)	1/3 (33.3)	3/6 (50.0)

^aFor PGTCS, no seizure-free patients received EIASMs

EIASM, enzyme-inducing anti-seizure medication; PGTCS, primary generalized tonic-clonic seizures; POS, partial-onset seizures; SGS, secondarily generalized seizures